CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 43 enrolled
Drug / intervention
Oleclumab +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03381274
NCT03381274Phase 2Active
CompareCT.gov

A Multiarm, Open-label, Multicenter, Phase 1b/2 Study to Evaluate Novel Combination Therapies in Subjects With Previously Treated Advanced EGFRm NSCLC

MedImmune LLC·interventional·Posted Dec 21, 2017·Updated Mar 11, 2026

In Brief

A Phase 2 clinical trial evaluating Oleclumab, Osimertinib, and 1 other intervention for Carcinoma, Non-Small-Cell Lung. Active but no longer recruiting, targeting 43 participants across 13 sites in 3 countries.

Detailed Summary

The objective of this study is to investigate the safety, tolerability, and antitumor activity of novel combination therapies administered in participants with advanced EGFRm NSCLC.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Non-Small-Cell Lung
CountriesSouth Korea, Taiwan, United States
Collaborators--

Timeline

Phase 2ActiveOverdue
201820192020202120222023202420252026
First PostedDec 21, 2017
Enrollment StartMay 8, 2018
Primary CompletionMay 24, 2021
Study CompletionApr 16, 2026
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 8.5 years ago

Interventions

Oleclumabbiological

Participants will receive oleclumab in combination with osimertinib or AZD4635 as stated in the arms' description.

Osimertinibdrug

Participants will receive osimertinib in combination with oleclumab as stated in the arms' description.

AZD4635drug

Participants will receive AZD4635 in combination with oleclumab as stated in the arms' description.